Wall Street analysts predict that Supernus Pharmaceuticals (NASDAQ:SUPN) will post $87.82 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The lowest sales estimate is $84.40 million and the highest is $92.17 million. Supernus Pharmaceuticals posted sales of $57.58 million during the same quarter last year, which suggests a positive year over year growth rate of 52.5%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $399.21 million for the current financial year, with estimates ranging from $387.10 million to $413.31 million. For the next financial year, analysts forecast that the business will report sales of $506.00 million per share, with estimates ranging from $478.42 million to $563.80 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.18. The company had revenue of $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%.
SUPN has been the subject of several research analyst reports. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 21st. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, January 10th. ValuEngine upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. B. Riley lifted their target price on Supernus Pharmaceuticals from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, December 28th. Finally, Berenberg Bank initiated coverage on Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 target price for the company. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.36.
In related news, VP Victor Vaughn sold 60,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $45.33, for a total value of $2,719,800.00. Following the completion of the sale, the vice president now directly owns 24,344 shares in the company, valued at $1,103,513.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the sale, the vice president now owns 32,500 shares of the company’s stock, valued at $1,561,300. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 26.5% in the fourth quarter. Flinton Capital Management LLC now owns 6,944 shares of the specialty pharmaceutical company’s stock valued at $277,000 after acquiring an additional 1,456 shares in the last quarter. Lenox Wealth Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 17.8% in the fourth quarter. Lenox Wealth Management Inc. now owns 10,119 shares of the specialty pharmaceutical company’s stock valued at $403,000 after acquiring an additional 1,531 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Supernus Pharmaceuticals by 7.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 22,100 shares of the specialty pharmaceutical company’s stock valued at $881,000 after acquiring an additional 1,600 shares in the last quarter. Essex Investment Management Co. LLC grew its stake in Supernus Pharmaceuticals by 3.0% in the fourth quarter. Essex Investment Management Co. LLC now owns 65,161 shares of the specialty pharmaceutical company’s stock valued at $2,597,000 after purchasing an additional 1,917 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Supernus Pharmaceuticals by 2.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 68,599 shares of the specialty pharmaceutical company’s stock valued at $2,734,000 after purchasing an additional 1,964 shares during the last quarter. Hedge funds and other institutional investors own 97.35% of the company’s stock.
Shares of NASDAQ:SUPN traded up $1.70 on Friday, hitting $48.05. 923,331 shares of the company’s stock were exchanged, compared to its average volume of 685,347. Supernus Pharmaceuticals has a 12 month low of $29.95 and a 12 month high of $50.04. The company has a market cap of $2,334.63, a price-to-earnings ratio of 38.37 and a beta of 1.11.
COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://ledgergazette.com/2018/04/18/supernus-pharmaceuticals-supn-expected-to-announce-quarterly-sales-of-87-82-million.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.